Trial Site Feasibility Platform Looks to End Onerous Paper Questionnaires

By Zachary Brennan

- Last updated on GMT

Online Trial Site Feasibility Tech Could End Onerous Questionnaires
Online Trial Site Feasibility Tech Could End Onerous Questionnaires
The antiquated process of evaluating clinical trial sites through paper questionnaires may be coming to an end thanks to a new online platform.

The standard 6-8 week process of filling out the questionnaires and waiting for a response from a sponsor or CRO running the trial may be overhauled by ViS Research’s online research feasibility platform, which ViS CEO Fabio Thiers MD, PhD told us can allow a site’s feasibility to be determined in an afternoon.

ViS recently announced a collaboration with the Biomedical Research Alliance of New York (BRANY), which is one of the largest networks of clinical research sites in the US.

Kimberly Irvine, executive vice president and COO of BRANY, told, “We know there’s a problem with the feasibility process​” because “a CRO can send these questionnaires to a whole host of trial sites and then the sites don’t hear back. They are investing a lot of time and effort for no return​.”

The ViS database, which is free for sponsors and CROs to browse through but costs money to access its analytics, aims to overhaul a process that is performed the “same way today as it was 40 years ago​,” Daniel Martines, CIO and executive director of ViS, told us.

He added that the platform includes evaluations of feasibility assessments over the last 10 years for trial sites in more than 80 countries and includes about 80% of the feasibility questions that sponsors and CROs typically ask.

With nearly half of all trial sites bringing between zero and two patients to a trial, CROs and sponsors are wasting time and resources. Ultimately this platform aims to reduce these issues, and bring promising drugs to market more quickly, Thiers added.

Related news

Show more

Related products

show more

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers